Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Otsuka Pharmaceutical Co., Ltd. |
---|---|
Information provided by: | Otsuka Pharmaceutical Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT00233389 |
To examine the efficacy of continued administration of rebamipide following bacteria eradication therapy in patients with H. pylori-positive active gastric ulcer in a placebo-controlled, double-blind study
Condition | Intervention | Phase |
---|---|---|
Stomach Ulcer |
Drug: Rebamipide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Post-Marketing Clinical Study of Rebamipide to Investigate the Gastric Ulcer Healing Effect of Continued Dosing Following Helicobacter Pylori Eradication Therapy |
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | C03700-003, JapicCTI-050035 |
Study First Received: | October 4, 2005 |
Last Updated: | May 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00233389 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Stomach Ulcer Antioxidants Stomach Diseases Digestive System Diseases |
Gastrointestinal Diseases Ulcer Rebamipide Peptic Ulcer |
Stomach Ulcer Antioxidants Molecular Mechanisms of Pharmacological Action Gastrointestinal Diseases Ulcer Physiological Effects of Drugs Gastrointestinal Agents Enzyme Inhibitors Protective Agents |
Rebamipide Pharmacologic Actions Digestive System Diseases Stomach Diseases Pathologic Processes Therapeutic Uses Anti-Ulcer Agents Peptic Ulcer |